Focus: Lexeo Therapeutics is a gene therapy biotech focused on rare and neurodegenerative diseases, headquartered in New York with early-stage clinical programs.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Early-stage gene therapy bet for scientists seeking cutting-edge research and upside potential, but career stability dependent on clinical trial success and capital markets sentiment.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lexeo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lexeo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Have Insiders Sold Lexeo Therapeutics Shares Recently? - simplywall.st
Have Insiders Sold Lexeo Therapeutics Shares Recently? simplywall.st
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? Yahoo Finance
LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares - Stock Titan
LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares Stock Titan
LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity - Stock Titan
LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity Stock Titan
Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale - Stock Titan
Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale Stock Titan
RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer - Stock Titan
RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo